RAPGEF1 and kidney disorder: The intensive research in the field of C3G, along with the evaluation of several complement-targeting therapeutics and inhibitors for C3G that are currently in phase II and phase III trials, gives a very promising situation, for providing effective treatment for this kidney disease in the near future and giving hope to patients and their families.